IRIDEX Corporation (IRIX)
| Market Cap | 46.32M |
| Revenue (ttm) | 51.87M |
| Net Income (ttm) | -9.57M |
| Shares Out | 16.25M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,339 |
| Open | 2.880 |
| Previous Close | 2.800 |
| Day's Range | 2.820 - 2.900 |
| 52-Week Range | 1.310 - 3.650 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retino... [Read more]
Financial Performance
In 2023, IRIDEX's revenue was $51.87 million, a decrease of -8.96% compared to the previous year's $56.97 million. Losses were -$9.57 million, 26.8% more than in 2022.
Financial StatementsNews
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first ...
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launc...
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex Reports Third Quarter 2023 Financial Results and Business Update
MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
The Company also announced plans to present at Stifel Healthcare Conference The Company also announced plans to present at Stifel Healthcare Conference
Iridex to Report Third Quarter Financial Results on November 14, 2023
MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Announces Strategic Review to Unlock Shareholder Value
MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advi...
Iridex to Report First Quarter Financial Results on May 11, 2023
MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...
Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth
Iridex to Present at the 35th Annual Roth Conference
MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...
Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
Five Events at Booth #5
Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth
Iridex to Participate in Fireside Chat with Stifel Equity Research
MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022
MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways t...
Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Announces Second Quarter 2022 Financial Results
MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.
Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022
MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...
Iridex Announces First Quarter 2022 Financial Results
Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue
Iridex to Report First Quarter 2022 Financial Results on May 12, 2022
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...
Iridex Announces the Appointment of Beverly Huss to its Board of Directors
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...